SOURCE: NeoStem, Inc.

December 04, 2006 16:50 ET

Three NeoStem Medical Experts Will Present Scientific Papers at Anti-Aging Conference in Las Vegas, December 7-10, 2006

NEW YORK, NY -- (MARKET WIRE) -- December 4, 2006 -- NeoStem, Inc. (OTCBB: NEOI), a company specializing in the collection, processing and long-term storage of Adult Stem Cells (ASCs) for autologous use ("Your cells for your use"), today announced that three medical experts affiliated with the Company will present papers at the 14th Annual International Congress on Anti-Aging Medicine, taking place at The Venetian in Las Vegas, December 7-10, 2006 (

On Thursday, December 7th, Dr. George S. Smith, M.D., Medical Director of the NeoStem, Inc. Biologics Laboratory in Los Angeles, will speak on "Newer Clinical Applications of Autologous Adult Stem Cells" (11:30AM-12:00PM), in Workshop #5 titled "Clinical Advances in Anti-Aging Medicine" (Room: Veronese 2403-2404). NeoStem's Biologics Laboratory specializes in the processing and long-term storage of adult peripheral blood stem cells and the Company expects to begin identifying and categorizing stem cell biomarkers which could lead to enhancing diagnostic and therapeutic applications.

On Saturday, December 9th, Denis O. Rodgerson, Ph.D., Director of Stem Cell Science at NeoStem, Inc., will present to the General Session on "Adult Peripheral Blood Stem Cell Banking" (4:00-4:30PM). Formerly Chairman of the Department of Clinical Chemistry and Toxicology at the University of California Los Angeles ("UCLA"), Dr. Rodgerson has published more than 150 professional articles and is the holder of several patents. He is the co-founder of StemCyte, where he oversaw the company to the world's second largest umbilical cord stem cell bank with multinational collection centers. His distinguished career has included being the Vice-Chairman and Professor of the Department of Pathology and Laboratory Medicine at UCLA and Director of Pediatric Laboratories and Analytical Toxicology Service at the University of Colorado.

On Thursday, December 7th, Dr. Ron Rothenberg, M.D., FACEP, will co-chair a day-long Workshop titled "Endocrinology: a Practical Application of Treating Adult Hormone Deficiency Using Bio-Identical Hormone Replacement Therapy" (Room: Veronese 2503-2504).

Dr. Rothenberg is a member of NeoStem's Advisory Board and an Adult Stem Cell Collection Provider in NeoStem's Physician's Network, launching in September 2006 a NeoStem Adult Stem Cell Collection Center at the California HealthSpan Institute in Encinitas, California. He will deliver several papers during the December 7th Workshop, including:

--  "DHEA - The Mother Hormone" (9:30-10:00AM),
--  "Adult Growth Deficiencies Treatments" (11:15AM - 12:00PM), and
--  "The Nuts and Bolts of Anti-Aging Medicine; 'How to Prescribe'
    Hormones for all Bio-Identical Hormones That are Used in a Hormone
    Replacement Practice" (4:30-5:30 PM).
Dr. Rothenberg will also speak at the General Session on Saturday, December 9th, on "The Anti-Aging Emergency Room: Hormone and Nutritional Treatment for Acute Medical Emergencies" (9:20-10:00AM).

Robin Smith, M.D., M.B.A., NeoStem's Chief Executive Officer, said, "We are very proud of the high-level expertise that the NeoStem team represents. We are building a company to serve the cutting edge of regenerative medical treatments, and we are bringing together some of the finest minds addressing these fields. The presentations by Drs. Smith [no relation], Rodgerson and Rothenberg provide important information about the potential of autologous adult stem cell applications."

About NeoStem, Inc.

NeoStem, Inc. (OTCBB: NEOI) is an innovative, publicly traded company positioned to become a leader in the adult stem cell field and to capitalize on the increasing importance adult stem cells are expected to play in the future of regenerative medicine.

Using its proprietary process, NeoStem provides the infrastructure, methods and systems that allow adults to have their stem cells safely collected and conveniently banked for future therapeutic use, as needed, in the treatment of such life-threatening diseases as diabetes, heart disease and radiation sickness that may result from a bio-terrorist attack. Adult stem cell therapy has also been used for many years in treating blood cancer. Further potential uses include regenerative therapies for wound healing, autoimmune diseases such as multiple sclerosis and lupus, and age-related degenerative musculoskeletal diseases.

NeoStem uses the least invasive form of collection called apheresis, a well known safe procedure that extracts stem cells from an adult's peripheral blood. Once collected, NeoStem's storage process allows the cells to be cryo-preserved during an individual's lifetime for use when needed. The management, Board of Directors and Advisors of NeoStem collectively have significant technical, medical and scientific expertise as well as substantial experience in life science marketing and business development.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the Company's ability to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of NeoStem's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business and obtain appropriate state licenses; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control and (v) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at under "Search for Company Filings."

Pursuant to a October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's Common Stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit

Contact Information

    Robin Smith, MD, MBA
    NeoStem, Inc.
    420 Lexington Ave, Suite 450
    NY, NY 10170
    Tel: (212) 584-4180
    Fax: (646) 514-7787
    E-mail: Email Contact
    Web site:

    Stanley Wunderlich / Daniel Stepanek
    Consulting for Strategic Growth 1
    800 Second Avenue
    New York, NY 10017
    Tel: (800) 625-2236 / (212) 896-1206
    Fax: (212) 337-8089
    Emails: Email Contact / Email Contact
    Web site: